✦ LIBER ✦

New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease

✍ Scribed by Darla R. Shores; David G. Binion; Bruce A. Freeman; Paul R.S. Baker

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 208 KB
Volume: 17
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.21560

No coin nor oath required. For personal study only.

✦ Synopsis

Dietary and endogenously modified lipids modulate inflammation by functioning as intra- and intercellular signaling molecules. Proinflammatory lipid mediators such as the eicosanoids compete against the signaling actions of newly discovered modified fatty acids that act to resolve inflammation. In inflammatory bowel disease, multiple aberrancies in lipid metabolism have been discovered, which shed further light on the pathogenesis of intestinal inflammation. Mechanisms by which lipids modulate inflammation, abnormalities of lipid metabolism in the setting of inflammatory bowel disease, and potential therapeutic application of lipid derivatives in this setting are discussed.

📜 SIMILAR VOLUMES

New insights into the role of IL-17 in i

New insights into the role of IL-17 in inflammatory bowel disease

✍ Ansu Mammen Noronha 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

New insights into the role of iron in th

New insights into the role of iron in the development of nonalcoholic fatty liver disease

✍ Paul A. Sharp 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

Role of diet in the development of infla

Role of diet in the development of inflammatory bowel disease

✍ Christine A. Chapman-Kiddell; Peter S.W. Davies; Lynda Gillen; Graham L. Radford 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

The inflammatory bowel diseases (IBDs) are a group of heterogeneous disorders characterized by acute and chronic inflammatory changes in the small or large bowel, or in both. Increasing incidence and prevalence figures for IBD both in the developed and developing world indicate that environmental fa

Drug development in inflammatory bowel d

Drug development in inflammatory bowel disease: The role of the FDA

✍ Conor Lahiff; Sunanda Kane; Alan C. Moss 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB 👁 2 views

All medicinal compounds sold in the United States for inflammatory bowel disease (IBD) are regulated by the Food and Drug Administration (FDA) via a number of regulations dating back to 1906. The primary contemporary role of the FDA is in the assessment of safety and efficacy, and subsequent marketi

The straw that stirs the drink: Insight

The straw that stirs the drink: Insight into the pathogenesis of inflammatory bowel disease revealed through the study of microflora-induced inflammation in genetically modified mice

✍ Bruce H. Horwitz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

Abnormal response to enteric microflora is a critical factor driving bowel inflammation in patients with inflammatory bowel disease (IBD). Mice with genetically engineered mutations have played a central role in both formulating this hypothesis and elucidating the mechanism that normally protect the

New players in the cytokine orchestra of

New players in the cytokine orchestra of inflammatory bowel disease

✍ Massimo C. Fantini; Giovanni Monteleone; Thomas T. MacDonald 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

In both Crohn's disease (CD) and ulcerative colitis, the pathologic process is almost certainly driven by an aberrant local immune response directed against normal components of the bacterial microflora. Mucosal immune cells interact with nonimmune cells such as epithelial cells and fibroblasts to p